Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | HuJCAR014 |
| Trade Name | |
| Synonyms | Anti-CD19-CAR Genetically Engineered Autologous T-lymphocytes huJCAR014 |
| Drug Descriptions |
HuJCAR014 comprises CD4+ and CD8+ autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) that consists of an anti-CD19 fragment linked to the 4-1BB (CD137) signaling domain and truncated human epidermal growth factor receptor, which has potential cytotoxic activity against CD19-expressing tumor cells (NCI Drug Dictionary). |
| DrugClasses | CD19 Antibody 21 |
| CAS Registry Number | NA |
| NCIT ID | C133191 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Cyclophosphamide + Fludarabine + HuJCAR014 | Cyclophosphamide Fludarabine HuJCAR014 | 0 | 1 |
| HuJCAR014 | HuJCAR014 | 0 | 0 |